Bryden Considine, DO

Articles by Bryden Considine, DO

Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer

ByBryden Considine, DO,Daniel P. Petrylak, MD

April 15th 2019

In this article, we review the current use of and future direction for genetic testing and tumor profiling in patients with metastatic castration-resistant prostate cancer.

Integrating Novel Targets and Precision Medicine Into Prostate Cancer Care-Part 1: The Non-Androgen–Targetable Pathways in Castration-Resistant Prostate Cancer

ByBryden Considine, DO,Daniel P. Petrylak, MD

March 13th 2019

Here, we review the current use and future direction of novel therapeutic targets in the treatment of castration-resistant prostate cancer.

Latest Updated Articles

Integrating Novel Targets and Precision Medicine Into Prostate Cancer Care-Part 1: The Non-Androgen–Targetable Pathways in Castration-Resistant Prostate Cancer
Published: March 13th 2019 | Updated:
Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer
Published: April 15th 2019 | Updated:

Bryden Considine, DO

Articles by Bryden Considine, DO

Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer

Integrating Novel Targets and Precision Medicine Into Prostate Cancer Care-Part 1: The Non-Androgen–Targetable Pathways in Castration-Resistant Prostate Cancer

Latest Updated Articles

Trending on CancerNetwork

How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?

64Cu-SAR-bisPSMA PET Detects More Prostate Cancer Lesions vs SOC

Comprehensive Cancer Database May Enhance Personalized Therapy

Single-Agent PD-1 Blockade Therapy Improves Responses in Desmoplastic Melanoma

FDA Grants Fast Track Designation to NG-350A For pMMR Rectal Cancer